Cargando…

Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease

BACKGROUND: The EQ-5D-5 L is a commonly used generic measure of health. This study aimed to evaluate the psychometric properties of the EQ-5D-5 L in patients with Graves’ disease (GD). METHODS: A prospective cohort of patients with GD recruited at three public hospitals in Hong Kong completed the EQ...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaodong, Chan, Wendy WL, Tang, Eric HM, Suen, Alex HY, Fung, Matrix MH, Woo, Yu Cho, Liu, Shirley YW, Lam, Cindy LK, Luo, Nan, Wong, Carlos KH, Lang, Brian HH
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426177/
https://www.ncbi.nlm.nih.gov/pubmed/37580816
http://dx.doi.org/10.1186/s12955-023-02177-z
_version_ 1785090002251677696
author Liu, Xiaodong
Chan, Wendy WL
Tang, Eric HM
Suen, Alex HY
Fung, Matrix MH
Woo, Yu Cho
Liu, Shirley YW
Lam, Cindy LK
Luo, Nan
Wong, Carlos KH
Lang, Brian HH
author_facet Liu, Xiaodong
Chan, Wendy WL
Tang, Eric HM
Suen, Alex HY
Fung, Matrix MH
Woo, Yu Cho
Liu, Shirley YW
Lam, Cindy LK
Luo, Nan
Wong, Carlos KH
Lang, Brian HH
author_sort Liu, Xiaodong
collection PubMed
description BACKGROUND: The EQ-5D-5 L is a commonly used generic measure of health. This study aimed to evaluate the psychometric properties of the EQ-5D-5 L in patients with Graves’ disease (GD). METHODS: A prospective cohort of patients with GD recruited at three public hospitals in Hong Kong completed the EQ-5D-5 L and ThyPRO-39 questionnaires at baseline, 1-month, and 6-month follow-ups. Convergent validity was tested by examining the Spearman correlation between EQ-5D-5 L and ThyPRO-39 scores at baseline. 1-month test-retest reliability was assessed by Intraclass Correlation Coefficient (ICC), Gwet’s Agreement Coefficient 2 (AC2), and percentage agreement. Responsiveness of EQ-5D-5 L index and EQ-VAS scores was assessed using effect size statistics (standardized effect size [SES] and standardized response mean [SRM]). RESULTS: Of 125 recruited patients, 101 (80.8%) and 100 (80.0%) patients were followed up at 1- and 6-month, respectively. For convergent validity, there was a moderate negative correlation between EQ-5D-5 L index or EQ-VAS score and ThyPRO-39 overall QoL-impact score (-0.350, -0.451), between EQ-VAS score and composite score (-0.483), and strong negative correlation between EQ-5D-5 L index score and composite score (-0.567). The Gwet’s AC2 and percentage agreement were the highest in self-care (0.964 and 0.967), followed by mobility (0.952 and 0.962), usual activities (0.934 and 0.948), pain/discomfort (0.801 and 0.887), and anxiety/depression (0.788 and 0.882). The ICC for the EQ-5D-5 L index and the EQ-VAS was 0.707 and 0.700. For patients who reported having ‘worsened’ health at 6-month follow-up, the SES and SRM were − 0.66 and − 0.42 for EQ-5D-5 L index and − 1.15 and − 1.00 for EQ-VAS, respectively. CONCLUSIONS: The EQ-5D-5 L demonstrated convergent validity, test-retest reliability, and responsiveness to worsened health status among patients with GD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12955-023-02177-z.
format Online
Article
Text
id pubmed-10426177
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104261772023-08-16 Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease Liu, Xiaodong Chan, Wendy WL Tang, Eric HM Suen, Alex HY Fung, Matrix MH Woo, Yu Cho Liu, Shirley YW Lam, Cindy LK Luo, Nan Wong, Carlos KH Lang, Brian HH Health Qual Life Outcomes Research BACKGROUND: The EQ-5D-5 L is a commonly used generic measure of health. This study aimed to evaluate the psychometric properties of the EQ-5D-5 L in patients with Graves’ disease (GD). METHODS: A prospective cohort of patients with GD recruited at three public hospitals in Hong Kong completed the EQ-5D-5 L and ThyPRO-39 questionnaires at baseline, 1-month, and 6-month follow-ups. Convergent validity was tested by examining the Spearman correlation between EQ-5D-5 L and ThyPRO-39 scores at baseline. 1-month test-retest reliability was assessed by Intraclass Correlation Coefficient (ICC), Gwet’s Agreement Coefficient 2 (AC2), and percentage agreement. Responsiveness of EQ-5D-5 L index and EQ-VAS scores was assessed using effect size statistics (standardized effect size [SES] and standardized response mean [SRM]). RESULTS: Of 125 recruited patients, 101 (80.8%) and 100 (80.0%) patients were followed up at 1- and 6-month, respectively. For convergent validity, there was a moderate negative correlation between EQ-5D-5 L index or EQ-VAS score and ThyPRO-39 overall QoL-impact score (-0.350, -0.451), between EQ-VAS score and composite score (-0.483), and strong negative correlation between EQ-5D-5 L index score and composite score (-0.567). The Gwet’s AC2 and percentage agreement were the highest in self-care (0.964 and 0.967), followed by mobility (0.952 and 0.962), usual activities (0.934 and 0.948), pain/discomfort (0.801 and 0.887), and anxiety/depression (0.788 and 0.882). The ICC for the EQ-5D-5 L index and the EQ-VAS was 0.707 and 0.700. For patients who reported having ‘worsened’ health at 6-month follow-up, the SES and SRM were − 0.66 and − 0.42 for EQ-5D-5 L index and − 1.15 and − 1.00 for EQ-VAS, respectively. CONCLUSIONS: The EQ-5D-5 L demonstrated convergent validity, test-retest reliability, and responsiveness to worsened health status among patients with GD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12955-023-02177-z. BioMed Central 2023-08-15 /pmc/articles/PMC10426177/ /pubmed/37580816 http://dx.doi.org/10.1186/s12955-023-02177-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Xiaodong
Chan, Wendy WL
Tang, Eric HM
Suen, Alex HY
Fung, Matrix MH
Woo, Yu Cho
Liu, Shirley YW
Lam, Cindy LK
Luo, Nan
Wong, Carlos KH
Lang, Brian HH
Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease
title Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease
title_full Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease
title_fullStr Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease
title_full_unstemmed Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease
title_short Psychometric properties of EQ-5D-5L for use in patients with Graves’ disease
title_sort psychometric properties of eq-5d-5l for use in patients with graves’ disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426177/
https://www.ncbi.nlm.nih.gov/pubmed/37580816
http://dx.doi.org/10.1186/s12955-023-02177-z
work_keys_str_mv AT liuxiaodong psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT chanwendywl psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT tangerichm psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT suenalexhy psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT fungmatrixmh psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT wooyucho psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT liushirleyyw psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT lamcindylk psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT luonan psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT wongcarloskh psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease
AT langbrianhh psychometricpropertiesofeq5d5lforuseinpatientswithgravesdisease